

Regd. Office :
"Zydus Tower",
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

December 21, 2011

Bombay Stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Attention: Mr. Sanjay Golecha
Mr. Gopalkrishnan

Fax No. 022 – 22722039 / 3121

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra- Kurla Complex
Bandra – (East)
Mumbai – 400 051

Attention: Famroze Pochara
Asst. Vice President

Fax No. 022 – 26598237/38

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjra Pole,
Ahmedabad – 380 015

Fax No. 079 - 26308877

Re.: Press Release

Dear Sir / Madam

We are pleased to inform you that the Company has acquired 100% stake in Biochem Pharmaceutical Industries Limited, one of the top 40 Pharma Companies in India, having its headquarter at Mumbai.


We enclose herewith a copy of press release dated 21st December, 2011 titled "Zydus acquires 100% stake in Mumbai based Biochem" to be released in the News Papers which gives the full details of the same.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED



UPEN H. SHAH
Company Secretary

Encl.: As above.

Zydus acquires 100% stake in Mumbai-based Biochem

Ahmedabad, December 21, 2011

Zydus Cadila has acquired 100% stake in Biochem, one of the top 40 pharma companies in India. A privately-held company headquartered in Mumbai, Biochem is a well-integrated pharma player with a presence in the antibiotics, cardiovascular, anti-diabetic and oncological segments. Biochem has reported sales of Rs. 264.5 crores for the year 2010-2011.

Established in 1959, Biochem has proven strengths in manufacturing and marketing of antibiotics. The top 5 brands of the company are Ampilox, Biotax, Monotax, Amicin and Zithrocin which together contribute to 40% of the company's sales. Three of Biochem's brands fall in the top 300 pharma brands of India. The acquisition strengthens Zydus' operations in the Indian pharma market.

Speaking on the latest acquisition, Zydus Cadila's Chairman and Managing Director, Mr. Pankaj R. Patel said, "The Formulations Business in India has always been the bulwark of our operations and we have looked at every strategic opportunity to grow and contribute to this market, either by way of novel initiatives, collaborations or acquisitions. Biochem represents the right fit as they have a significant presence in our core therapy areas and also add value to our product offerings in the key growth segments."

###